tiprankstipranks
Trending News
More News >
Prothena (PRTA)
NASDAQ:PRTA
US Market
Advertisement

Prothena (PRTA) Stock Forecast & Price Target

Compare
664 Followers
See the Price Targets and Ratings of:

PRTA Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
4 Buy
3 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Prothena
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRTA Stock 12 Month Forecast

Average Price Target

$12.00
▲(40.35% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $12.00 with a high forecast of $18.00 and a low forecast of $4.00. The average price target represents a 40.35% change from the last price of $8.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","8":"$8","13":"$13","18":"$18","23":"$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8,13,18,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.27,9.018461538461539,9.766923076923076,10.515384615384615,11.263846153846153,12.012307692307692,12.760769230769231,13.509230769230768,14.257692307692308,15.006153846153847,15.754615384615384,16.503076923076925,17.251538461538463,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.27,8.556923076923077,8.843846153846153,9.13076923076923,9.417692307692308,9.704615384615384,9.991538461538461,10.278461538461539,10.565384615384616,10.852307692307692,11.13923076923077,11.426153846153845,11.713076923076922,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.27,7.941538461538461,7.613076923076923,7.2846153846153845,6.956153846153846,6.627692307692308,6.299230769230769,5.97076923076923,5.642307692307693,5.313846153846153,4.985384615384616,4.656923076923077,4.328461538461538,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.27,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$18.00Average Price Target$12.00Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on PRTA
Citizens JMP
Citizens JMP
$29$11
Buy
28.65%
Upside
Reiterated
09/02/25
Prothena price target lowered to $11 from $29 at Citizens JMPProthena price target lowered to $11 from $29 at Citizens JMP
Piper Sandler Analyst forecast on PRTA
Piper Sandler
Piper Sandler
$81$15
Buy
75.44%
Upside
Reiterated
08/28/25
Prothena price target lowered to $15 from $81 at Piper SandlerProthena price target lowered to $15 from $81 at Piper Sandler
Chardan Capital Analyst forecast on PRTA
Chardan Capital
Chardan Capital
$18
Buy
110.53%
Upside
Reiterated
08/28/25
Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Jazz Pharmaceuticals (NASDAQ: JAZZ)we reiterate our Buy rating of the stock
Bank of America Securities Analyst forecast on PRTA
Bank of America Securities
Bank of America Securities
$4
Sell
-53.22%
Downside
Reiterated
08/14/25
Bank of America Securities Remains a Sell on Prothena (PRTA)
H.C. Wainwright Analyst forecast on PRTA
H.C. Wainwright
H.C. Wainwright
$14
Buy
63.74%
Upside
Reiterated
08/05/25
Prothena's Strategic Initiatives and Promising Alzheimer's Pipeline Drive Buy RatingValuation and Risks. Our price target of $14 is based on an equally weighted composite of (a) $18.54/share, as a 20x multiple of taxed and diluted $3 discounted back to 12/31/2025 at 14%, and (b) an NPV of $10/share (discount rate 14.0%, growth rate 1.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development stage biotechnology company.
RBC Capital Analyst forecast on PRTA
RBC Capital
RBC Capital
$18$10
Hold
16.96%
Upside
Reiterated
08/05/25
Prothena Corp (PRTA) PT Lowered to $10 at RBC CapitalRBC Capital analyst Brian Abrahams lowered the price target on Prothena Corp (NASDAQ: PRTA) to $10.00 (from $18.00) while maintaining a Sector Perform rating.
Cantor Fitzgerald Analyst forecast on PRTA
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterated
06/20/25
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)
Oppenheimer Analyst forecast on PRTA
Oppenheimer
Oppenheimer
Hold
Reiterated
06/16/25
Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)
Jefferies Analyst forecast on PRTA
Jefferies
Jefferies
$32$6
Hold
-29.82%
Downside
Downgraded
05/27/25
Prothena's Hold Rating: Clinical Trial Challenges and Financial PressuresJefferies analyst Michael Yee downgraded Prothena Corp (NASDAQ: PRTA) from Buy to Hold with a price target of $6.00 (from $32.00).
Evercore ISI Analyst forecast on PRTA
Evercore ISI
Evercore ISI
Buy
Reiterated
02/21/25
Analysts Are Bullish on Top Healthcare Stocks: Prothena (PRTA), Dexcom (DXCM)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citizens JMP Analyst forecast on PRTA
Citizens JMP
Citizens JMP
$29$11
Buy
28.65%
Upside
Reiterated
09/02/25
Prothena price target lowered to $11 from $29 at Citizens JMPProthena price target lowered to $11 from $29 at Citizens JMP
Piper Sandler Analyst forecast on PRTA
Piper Sandler
Piper Sandler
$81$15
Buy
75.44%
Upside
Reiterated
08/28/25
Prothena price target lowered to $15 from $81 at Piper SandlerProthena price target lowered to $15 from $81 at Piper Sandler
Chardan Capital Analyst forecast on PRTA
Chardan Capital
Chardan Capital
$18
Buy
110.53%
Upside
Reiterated
08/28/25
Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Jazz Pharmaceuticals (NASDAQ: JAZZ)we reiterate our Buy rating of the stock
Bank of America Securities Analyst forecast on PRTA
Bank of America Securities
Bank of America Securities
$4
Sell
-53.22%
Downside
Reiterated
08/14/25
Bank of America Securities Remains a Sell on Prothena (PRTA)
H.C. Wainwright Analyst forecast on PRTA
H.C. Wainwright
H.C. Wainwright
$14
Buy
63.74%
Upside
Reiterated
08/05/25
Prothena's Strategic Initiatives and Promising Alzheimer's Pipeline Drive Buy RatingValuation and Risks. Our price target of $14 is based on an equally weighted composite of (a) $18.54/share, as a 20x multiple of taxed and diluted $3 discounted back to 12/31/2025 at 14%, and (b) an NPV of $10/share (discount rate 14.0%, growth rate 1.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development stage biotechnology company.
RBC Capital Analyst forecast on PRTA
RBC Capital
RBC Capital
$18$10
Hold
16.96%
Upside
Reiterated
08/05/25
Prothena Corp (PRTA) PT Lowered to $10 at RBC CapitalRBC Capital analyst Brian Abrahams lowered the price target on Prothena Corp (NASDAQ: PRTA) to $10.00 (from $18.00) while maintaining a Sector Perform rating.
Cantor Fitzgerald Analyst forecast on PRTA
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterated
06/20/25
Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)
Oppenheimer Analyst forecast on PRTA
Oppenheimer
Oppenheimer
Hold
Reiterated
06/16/25
Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)
Jefferies Analyst forecast on PRTA
Jefferies
Jefferies
$32$6
Hold
-29.82%
Downside
Downgraded
05/27/25
Prothena's Hold Rating: Clinical Trial Challenges and Financial PressuresJefferies analyst Michael Yee downgraded Prothena Corp (NASDAQ: PRTA) from Buy to Hold with a price target of $6.00 (from $32.00).
Evercore ISI Analyst forecast on PRTA
Evercore ISI
Evercore ISI
Buy
Reiterated
02/21/25
Analysts Are Bullish on Top Healthcare Stocks: Prothena (PRTA), Dexcom (DXCM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Prothena

1 Month
xxx
Success Rate
6/22 ratings generated profit
27%
Average Return
-3.69%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 27.27% of your transactions generating a profit, with an average return of -3.69% per trade.
3 Months
xxx
Success Rate
7/22 ratings generated profit
32%
Average Return
-7.17%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 31.82% of your transactions generating a profit, with an average return of -7.17% per trade.
1 Year
Jason ButlerCitizens JMP
Success Rate
4/22 ratings generated profit
18%
Average Return
-28.00%
reiterated a buy rating 5 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -28.00% per trade.
2 Years
xxx
Success Rate
2/15 ratings generated profit
13%
Average Return
-56.97%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -56.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRTA Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
8
8
8
5
5
Buy
0
0
0
0
1
Hold
10
12
14
11
7
Sell
1
1
1
0
0
Strong Sell
0
0
0
1
1
total
19
21
23
17
14
In the current month, PRTA has received 6 Buy Ratings, 7 Hold Ratings, and 1 Sell Ratings. PRTA average Analyst price target in the past 3 months is 12.00.
Each month's total comprises the sum of three months' worth of ratings.

PRTA Financial Forecast

PRTA Earnings Forecast

Next quarter’s earnings estimate for PRTA is -$0.69 with a range of -$1.16 to -$0.44. The previous quarter’s EPS was -$2.34. PRTA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.84% of the time in the same period. In the last calendar year PRTA has Outperformed its overall industry.
Next quarter’s earnings estimate for PRTA is -$0.69 with a range of -$1.16 to -$0.44. The previous quarter’s EPS was -$2.34. PRTA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.84% of the time in the same period. In the last calendar year PRTA has Outperformed its overall industry.

PRTA Sales Forecast

Next quarter’s sales forecast for PRTA is $6.64M with a range of $0.00 to $37.50M. The previous quarter’s sales results were $4.42M. PRTA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 55.74% of the time in the same period. In the last calendar year PRTA has Preformed in-line its overall industry.
Next quarter’s sales forecast for PRTA is $6.64M with a range of $0.00 to $37.50M. The previous quarter’s sales results were $4.42M. PRTA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 55.74% of the time in the same period. In the last calendar year PRTA has Preformed in-line its overall industry.

PRTA Stock Forecast FAQ

What is PRTA’s average 12-month price target, according to analysts?
Based on analyst ratings, Prothena’s 12-month average price target is 12.00.
    What is PRTA’s upside potential, based on the analysts’ average price target?
    Prothena has 40.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRTA a Buy, Sell or Hold?
          Prothena has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Prothena’s price target?
            The average price target for Prothena is 12.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $18.00 ,the lowest forecast is $4.00. The average price target represents 40.35% Increase from the current price of $8.55.
              What do analysts say about Prothena?
              Prothena’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of PRTA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis